Neumora initiates Phase 2 study of navacaprant in bipolar depression
PremiumThe FlyNeumora initiates Phase 2 study of navacaprant in bipolar depression
2M ago
Neumora Therapeutics Announces Initiation of Phase 2 Study of Navacaprant in Bipolar Depression
PremiumPress Releases
Neumora Therapeutics Announces Initiation of Phase 2 Study of Navacaprant in Bipolar Depression
2M ago
Neumora Therapeutics reports Q1 EPS (34c), consensus (34c)
PremiumThe Fly
Neumora Therapeutics reports Q1 EPS (34c), consensus (34c)
3M ago
Neumora weakness amid lock-up expiration a buying opportunity, says RBC Capital
PremiumThe FlyNeumora weakness amid lock-up expiration a buying opportunity, says RBC Capital
5M ago
Neumora weakness amid lock-up expiration a buying opportunity, says RBC Capital
PremiumThe Fly
Neumora weakness amid lock-up expiration a buying opportunity, says RBC Capital
5M ago
Neumora Therapeutics to Participate at Stifel 2024 Virtual CNS Days
PremiumPress Releases
Neumora Therapeutics to Participate at Stifel 2024 Virtual CNS Days
5M ago
JPMorgan biotech analysts to hold an analyst/industry conference call
PremiumThe FlyJPMorgan biotech analysts to hold an analyst/industry conference call
5M ago
Neumora Therapeutics appoints Panandiker as Chief Commercial Officer
PremiumThe Fly
Neumora Therapeutics appoints Panandiker as Chief Commercial Officer
6M ago
Neumora Therapeutics Appoints Kaya Pai Panandiker as Chief Commercial Officer
PremiumPress Releases
Neumora Therapeutics Appoints Kaya Pai Panandiker as Chief Commercial Officer
6M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100